Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

Inclusion Criteria: * High-grade carciomas of the ovary, fallopian tube, or periteonum, based on local pathology review, including high grade serous carcinoma, high grade endometrioid carcinomas, clear cell carcinoma, and carcinosarcoma. * Platinum-refractory or resistant disease, as defined by progressive disease while receiving platinum-based chemotherapy or with recurrent disease \< 6 months after the completion of platinum-based chemotherapy. * May have received up to 2 prior therapies for platinum-resistant ovarian cancer. * Must have received prior-platinum-based chemotherapy. * BRCA1, BRCA2, RAD51, BRIP1, ATM, FANCL, PALB2 and other FA/BRCA pathway gene wild-type. * Tumor HR-proficient, as assessed by Myriad myChoice HRD Test (HRD score \< 42). * Provision of informed consent prior to any study specific procedures * Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment as defined below: * Haemoglobin ≥ 10.0 g/dL with no blood transfusion in the past 28 days * Absolute neutrophil count (ANC) ≥ 1.5 x 109 /L * Platelet count ≥ 100 x 109 /L * Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) * Aspartate aminotransferase (AST) (Serum Glutamic Oxaloacetic Transaminase (SGOT)) / Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT)) ≤ 2.5 x institutional upper limit of normal unless liver metastases are present in which case they must be ≤ 5x ULN * Patient…